Aurinia Pharmaceuticals Inc (AUPH)

[moosedogger]

...they picked patient comfort over efficacy.

There's a very strange irony with that decision.

They got P2 and P3 .001 efficacy in LN because Voclosporin's effect could be measured objectively.

It's so bizarre Aurinia would pick a subjective measure in DES when they could have followed their successful strategy of objective measurements.

Very, very strange. On a related note, the recent patent infringement lawsuit that Aurinia filed suggests their DES (VOS) program isn't completely dead.

McDermott Will & Emery filed a lawsuit Friday in New Jersey District Court on behalf of Aurinia Pharmaceuticals. The complaint, which claims infringement of a patent for an ophthalmic solution, targets Sun Pharmaceutical Industries and other defendants. Counsel have not yet appeared for the defendants. The case is 3:20-cv-19805, Aurinia Pharmaceuticals Inc. v. Sun Pharmaceutical Industries Inc. et al.